Loading...

MGC Pharmaceuticals Limited

MXC.L•LSE
HealthcareDrug Manufacturers - Specialty & Generic
£21.20
£-0.80(-3.64%)

MGC Pharmaceuticals Limited (MXC.L) Stock Overview

Explore MGC Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for MXC.LStats details for MXC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for MXC.LAnalyst Recommendations details for MXC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

CEO

Mr. Roby Reuven Zomer

Headquarters

1202 Hay Street, West Perth, WA

Founded

2021

Frequently Asked Questions